바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

572누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

AntibodystaleEli LillyPhase 3

Cetuximab + concomitant boost radiotherapy (Cetuximab + concomitant boost radiotherapy)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

CGTBiologicstaleUNC Lineberger Comprehensive Ca…Phase 1

ATLCAR.CD30.CCR4 cells (ATLCAR.CD30.CCR4 cells)

Lymphoma; Immune System Diseases · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 2

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

Hodgkin's Disease; Lymphoma · Hodgkin's Disease

#HodgkinsDisease#Antibody#Phase2#항체#면역항체+3

효능 ORR 32%임상시험 1상태 ACTIVE

AntibodystaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

Malignant Melanoma Stage III · Malignant Melanoma Stage III

#MalignantMelanomaStageIII#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleKang YUPreclinical

CAR-CD19 T cell (CAR-CD19 T cell)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+4

효능 ORR 67%임상시험 1상태 ACTIVE

CGTBiologicstaleUNC Lineberger Comprehensive Ca…Phase 1

ALTCAR.CD30 cells (ALTCAR.CD30 cells)

Lymphoma; Immune System Diseases · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Objective Response Rate · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

ADCBiologicstaleAcademic and Community Cancer R…Phase 2

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Breast Adenocarcinoma; Stage II Breast Cancer AJCC v6 and v7 · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 ACTIVE

AntibodystaleJanssenApproved

Infliximab and immunosuppressives (Infliximab and immunosuppressives)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleJanssenApproved

Infliximab-Innovator (Infliximab-Innovator)

Colitis, Ulcerative; Crohn's Disease · Colitis, Ulcerative

#ColitisUlcerative#Antibody#Approved#항체#면역항체+5

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI)

Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

ADCBiologicstaleTakedaPhase 2

TAK-853 (TAK-853)

Ovarian Cancer; Solid Tumors · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 44%임상시험 1상태 RECRUITING

ADCBiologicstaleShanghai Fudan-Zhangjiang Bio-P…Phase 1

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 ACTIVE

AntibodystaleAbbViePhase 3

adalimumab (Humira, azathioprine or adalimumab and infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

ADCBiologicstaleTagworks Pharmaceuticals BVPhase 1

TGW101 (TGW101)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 ACTIVE

ADCBiologicstaleEli Lilly and CompanyPhase 1

LY3076226 (LY3076226)

Advanced Cancer; Metastatic Cancer · Advanced Cancer

#AdvancedCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 ACTIVE

ADCBiologicstaleByondis B.V.Phase 1

BYON3521 (BYON3521)

Solid Tumor · Solid Tumor

#SolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 ACTIVE

ADCBiologicstaleBayerPhase 1

BAY1862864 (BAY1862864)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 ACTIVE

ADCBiologicstaleAmgenPhase 1

AMG 172 (AMG 172)

Renal Cell Adenocarcinoma; Clear Cell Renal Carcinoma · Renal Cell Adenocarcinoma

#RenalCellAdenocarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 2

Rituximab, lenalidomide (Rituximab, lenalidomide)

Primary CNS Lymphoma · Primary CNS Lymphoma

#PrimaryCNSLymphoma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

ADCBiologicstaleBeOne MedicinesPhase 1

BG-C0902 (BG-C0902)

Solid Tumors; Advanced Solid Tumor · Solid Tumors

#SolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

ADCBiologicstaleVanderbilt-Ingram Cancer CenterPhase 1

[68Ga]Ga-ABY-025 ([68Ga]Ga-ABY-025)

Locally Advanced Cancer; Metastatic Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

ADCBiologicstaleShanghai Fudan-Zhangjiang Bio-P…Phase 1

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 ACTIVE

AntibodystaleMerckPhase 2

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

Unresectable Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 DISCONTINUED

62 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 572

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

Cetuximab + concomitant boost radiotherapy (Cetuximab + concomitant boost radiotherapy)

ATLCAR.CD30.CCR4 cells (ATLCAR.CD30.CCR4 cells)

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

CAR-CD19 T cell (CAR-CD19 T cell)

ALTCAR.CD30 cells (ALTCAR.CD30 cells)

CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Infliximab and immunosuppressives (Infliximab and immunosuppressives)

Infliximab-Innovator (Infliximab-Innovator)

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI)

TAK-853 (TAK-853)

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib)

adalimumab (Humira, azathioprine or adalimumab and infliximab)

TGW101 (TGW101)

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

LY3076226 (LY3076226)

BYON3521 (BYON3521)

BAY1862864 (BAY1862864)

AMG 172 (AMG 172)

Rituximab, lenalidomide (Rituximab, lenalidomide)

BG-C0902 (BG-C0902)

[68Ga]Ga-ABY-025 ([68Ga]Ga-ABY-025)

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia)

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Cetuximab + concomitant boost radiotherapy (Cetuximab + concomitant boost radiotherapy)

ATLCAR.CD30.CCR4 cells (ATLCAR.CD30.CCR4 cells)

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

CAR-CD19 T cell (CAR-CD19 T cell)

ALTCAR.CD30 cells (ALTCAR.CD30 cells)

CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Infliximab and immunosuppressives (Infliximab and immunosuppressives)

Infliximab-Innovator (Infliximab-Innovator)

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI)

TAK-853 (TAK-853)

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib)

adalimumab (Humira, azathioprine or adalimumab and infliximab)

TGW101 (TGW101)

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

LY3076226 (LY3076226)

BYON3521 (BYON3521)

BAY1862864 (BAY1862864)

AMG 172 (AMG 172)

Rituximab, lenalidomide (Rituximab, lenalidomide)

BG-C0902 (BG-C0902)

[68Ga]Ga-ABY-025 ([68Ga]Ga-ABY-025)

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia)

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Cetuximab + concomitant boost radiotherapy (Cetuximab + concomitant boost radiotherapy)

ATLCAR.CD30.CCR4 cells (ATLCAR.CD30.CCR4 cells)

rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim (rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim)

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

CAR-CD19 T cell (CAR-CD19 T cell)

ALTCAR.CD30 cells (ALTCAR.CD30 cells)

CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)

Multi-epitope HER2 Peptide Vaccine TPIV100 (Multi-epitope HER2 Peptide Vaccine TPIV100)

Infliximab and immunosuppressives (Infliximab and immunosuppressives)

Infliximab-Innovator (Infliximab-Innovator)

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI (Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI)

TAK-853 (TAK-853)

FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib (FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib)

adalimumab (Humira, azathioprine or adalimumab and infliximab)

TGW101 (TGW101)

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)